Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

NCT06794229 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Renal Cell Carcinoma

Interventions

DRUG: Zanzalintinib
DRUG: Nivolumab

Sponsor

Qian Qin

Collaborators

[object Object]
[object Object]